Sever's disease Treatment market poised to grow at highest pace owing to increasing pediatric obesity

The severs disease treatment market is primarily driven by increasing cases of severs disease among school-going children and rising pediatric obesity. Sever's disease, also known as calcaneal apophysitis, is a common cause of heel pain in children that affects the growth plate of the heel bone. Symptoms include pain in the heel which is intensified by physical activity such as running, jumping, and walking. Treatment focuses on reducing pain and inflammation through the use of rest, ice packs, stretching, heel pads or cups, orthotic devices, anti-inflammatory medications, injections and in some cases surgery.

The global severs disease treatment market is estimated to be valued at US$ 1.34 Bn in 2024 and is expected to exhibit a CAGR of 4.9% over the forecast period 2024 to 2031.
Rising rates of overweight and obesity in children are contributing to the growth of this disease and hence fueling the Severs Disease Treatment Market Demand. According to WHO, over 340 million children and adolescents aged 5-19 were overweight or obese in 2016. Additionally, growing participation in sports and changing lifestyle patterns are also increasing the instance of severs disease and propelling the demand for effective treatments.

Key Takeaways

Key players operating in the severs disease treatment are AstraZeneca, Horizon Therapeutics plc, Sanofi, Novartis AG, Sun Pharmaceutical Industries Ltd., Cipla Inc., LEO Pharma A/S, AbbVie Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma, Lonza, Lupin, Dr. Reddy's Laboratories Ltd., IBSA Institut Biochimique SA. These players are focused on developing advanced medications and treatments to effectively manage pain and other severs disease symptoms.
Get More Insights on- Sever's disease Treatment market